EGFR and lung cancer: Having worked on lung cancer from the first use of epidermal growth factor receptor (EGFR) in patient genotyping, Prof Johnson offered insights into new targets, including MET and BRAF mutations, and how new sequencing technologies are matching patients to novel treatments with boosted survival rates from the French Cooperative Thoracic Group.